Literature DB >> 19605883

A maximum likelihood estimator of a Markov model for disease activity in Crohn's disease and ulcerative colitis for annually aggregated partial observations.

Sixten Borg1, Ulf Persson, Tine Jess, Ole Østergaard Thomsen, Tryggve Ljung, Lene Riis, Pia Munkholm.   

Abstract

Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases that have a remitting, relapsing nature. During relapse, they are treated with drugs and surgery. The present study was based on individual data from patients diagnosed with CD or UC at Herlev University Hospital, Copenhagen, Denmark, during 1991 to 1993. The data were aggregated over calendar years; for each year, the number of relapses and the number of surgical operations were recorded. Our aim was to estimate Markov models for disease activity in CD and UC, in terms of relapse and remission, with a cycle length of 1 month. The purpose of these models was to enable evaluation of interventions that would shorten relapses or postpone future relapses. An exact maximum likelihood estimator was developed that disaggregates the yearly observations into monthly transition probabilities between remission and relapse. These probabilities were allowed to be dependent on the time since start of relapse and on the time since start of remission, respectively. The estimator, initially slow, was successfully optimized to shorten the execution time. The estimated disease activity model for CD fits well to observed data and has good face validity. The disease activity model is less suitable for UC due to its transient nature through the presence of curative surgery.

Entities:  

Mesh:

Year:  2009        PMID: 19605883     DOI: 10.1177/0272989X09336141

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  3 in total

1.  Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study.

Authors:  Linwei Wang; Emanuel Krebs; Jeong E Min; W Christopher Mathews; Ank Nijhawan; Charurut Somboonwit; Judith A Aberg; Richard D Moore; Kelly A Gebo; Bohdan Nosyk
Journal:  Lancet HIV       Date:  2019-07-11       Impact factor: 12.767

2.  HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011.

Authors:  Bohdan Nosyk; Jeong Min; Viviane D Lima; Benita Yip; Robert S Hogg; Julio S G Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

Review 3.  A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases.

Authors:  Shmuel Odes; Dan Greenberg
Journal:  Clinicoecon Outcomes Res       Date:  2014-10-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.